selection should consider presence of cardiovascular disease, heart failure, or chronic kidney disease DPP-4 inhibitors (such as sitagliptin or linagliptin) oral agents with a different mechanism Insulin therapy particularly if glycaemic control is inadequate with oral agents Pioglitazone may be appropriate in selected patients without heart failure Sulfonylureas (such as gliclazide) though associated with hypoglycaemia and weight gain Your diabetes specialist or GP will conduct a comprehensive review of your treatment plan, considering factors such as HbA1c targets, cardiovascular risk profile, renal function, and personal preferences
If you are losing weight at a healthy, steady rate and your side effects are minimal, your provider may decide to keep you at your current dose rather than increasing it
(The FDA has received more than 700 adverse event reports tied to compounded GLP-1s, but its not clear if the events were caused by the drugs.) The companies also see compounders as a threat to their obesity drug sales, which are estimated to balloon to $100 billion a year by 2030
Aid for those with GSTP1, GSTM1 and GPX Gene mutations
The medication helps reduce cravings for sugar and alcohol, both of which increase results.